These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

504 related items for PubMed ID: 25682184

  • 1. The prognostic value of PD-L1 expression for non-small cell lung cancer patients: a meta-analysis.
    Wang A, Wang HY, Liu Y, Zhao MC, Zhang HJ, Lu ZY, Fang YC, Chen XF, Liu GT.
    Eur J Surg Oncol; 2015 Apr; 41(4):450-6. PubMed ID: 25682184
    [Abstract] [Full Text] [Related]

  • 2. PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma.
    Cooper WA, Tran T, Vilain RE, Madore J, Selinger CI, Kohonen-Corish M, Yip P, Yu B, O'Toole SA, McCaughan BC, Yearley JH, Horvath LG, Kao S, Boyer M, Scolyer RA.
    Lung Cancer; 2015 Aug; 89(2):181-8. PubMed ID: 26024796
    [Abstract] [Full Text] [Related]

  • 3. PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups.
    Schmidt LH, Kümmel A, Görlich D, Mohr M, Bröckling S, Mikesch JH, Grünewald I, Marra A, Schultheis AM, Wardelmann E, Müller-Tidow C, Spieker T, Schliemann C, Berdel WE, Wiewrodt R, Hartmann W.
    PLoS One; 2015 Aug; 10(8):e0136023. PubMed ID: 26313362
    [Abstract] [Full Text] [Related]

  • 4. Reliability of Small Biopsy Samples Compared With Resected Specimens for the Determination of Programmed Death-Ligand 1 Expression in Non--Small-Cell Lung Cancer.
    Kitazono S, Fujiwara Y, Tsuta K, Utsumi H, Kanda S, Horinouchi H, Nokihara H, Yamamoto N, Sasada S, Watanabe S, Asamura H, Tamura T, Ohe Y.
    Clin Lung Cancer; 2015 Sep; 16(5):385-90. PubMed ID: 25937270
    [Abstract] [Full Text] [Related]

  • 5. Impact of PD-L1 Expression in Patients with Surgically Resected Non-Small-Cell Lung Cancer.
    Igawa S, Sato Y, Ryuge S, Ichinoe M, Katono K, Hiyoshi Y, Otani S, Nagashio R, Nakashima H, Katagiri M, Sasaki J, Murakumo Y, Satoh Y, Masuda N.
    Oncology; 2017 Sep; 92(5):283-290. PubMed ID: 28222447
    [Abstract] [Full Text] [Related]

  • 6. PD-L1 Is Upregulated by Simultaneous Amplification of the PD-L1 and JAK2 Genes in Non-Small Cell Lung Cancer.
    Ikeda S, Okamoto T, Okano S, Umemoto Y, Tagawa T, Morodomi Y, Kohno M, Shimamatsu S, Kitahara H, Suzuki Y, Fujishita T, Maehara Y.
    J Thorac Oncol; 2016 Jan; 11(1):62-71. PubMed ID: 26762740
    [Abstract] [Full Text] [Related]

  • 7. Association of PD-1, PD-L1, and CTLA-4 Gene Expression and Clinicopathologic Characteristics in Patients With Non-Small-Cell Lung Cancer.
    Lafuente-Sanchis A, Zúñiga Á, Estors M, Martínez-Hernández NJ, Cremades A, Cuenca M, Galbis JM.
    Clin Lung Cancer; 2017 Mar; 18(2):e109-e116. PubMed ID: 27816393
    [Abstract] [Full Text] [Related]

  • 8. Functional polymorphisms in PD-L1 gene are associated with the prognosis of patients with early stage non-small cell lung cancer.
    Lee SY, Jung DK, Choi JE, Jin CC, Hong MJ, Do SK, Kang HG, Lee WK, Seok Y, Lee EB, Jeong JY, Shin KM, Yoo SS, Lee J, Cha SI, Kim CH, Park JY.
    Gene; 2017 Jan 30; 599():28-35. PubMed ID: 27838455
    [Abstract] [Full Text] [Related]

  • 9. Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer.
    Calles A, Liao X, Sholl LM, Rodig SJ, Freeman GJ, Butaney M, Lydon C, Dahlberg SE, Hodi FS, Oxnard GR, Jackman DM, Jänne PA.
    J Thorac Oncol; 2015 Dec 30; 10(12):1726-35. PubMed ID: 26473645
    [Abstract] [Full Text] [Related]

  • 10. Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers.
    Carbognin L, Pilotto S, Milella M, Vaccaro V, Brunelli M, Caliò A, Cuppone F, Sperduti I, Giannarelli D, Chilosi M, Bronte V, Scarpa A, Bria E, Tortora G.
    PLoS One; 2015 Dec 30; 10(6):e0130142. PubMed ID: 26086854
    [Abstract] [Full Text] [Related]

  • 11. Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer.
    McLaughlin J, Han G, Schalper KA, Carvajal-Hausdorf D, Pelekanou V, Rehman J, Velcheti V, Herbst R, LoRusso P, Rimm DL.
    JAMA Oncol; 2016 Jan 30; 2(1):46-54. PubMed ID: 26562159
    [Abstract] [Full Text] [Related]

  • 12. Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes.
    Yang CY, Lin MW, Chang YL, Wu CT, Yang PC.
    Eur J Cancer; 2014 May 30; 50(7):1361-9. PubMed ID: 24548766
    [Abstract] [Full Text] [Related]

  • 13. Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: Comparison of sarcomatous and carcinomatous areas.
    Kim S, Kim MY, Koh J, Go H, Lee DS, Jeon YK, Chung DH.
    Eur J Cancer; 2015 Nov 30; 51(17):2698-707. PubMed ID: 26329973
    [Abstract] [Full Text] [Related]

  • 14. A meta-analysis of STAT3 and phospho-STAT3 expression and survival of patients with non-small-cell lung cancer.
    Xu YH, Lu S.
    Eur J Surg Oncol; 2014 Mar 30; 40(3):311-7. PubMed ID: 24332948
    [Abstract] [Full Text] [Related]

  • 15. Significance of programmed cell death-ligand 1 expression and its association with survival in patients with small cell lung cancer.
    Ishii H, Azuma K, Kawahara A, Yamada K, Imamura Y, Tokito T, Kinoshita T, Kage M, Hoshino T.
    J Thorac Oncol; 2015 Mar 30; 10(3):426-30. PubMed ID: 25384063
    [Abstract] [Full Text] [Related]

  • 16. PD-L1 over-expression is associated with a poor prognosis in Asian non-small cell lung cancer patients.
    Xia H, Shen J, Hu F, Chen S, Huang H, Xu Y, Ma H.
    Clin Chim Acta; 2017 Jun 30; 469():191-194. PubMed ID: 28188721
    [Abstract] [Full Text] [Related]

  • 17. Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports.
    Xu TP, Shen H, Liu LX, Shu YQ.
    Gene; 2013 Sep 10; 526(2):265-74. PubMed ID: 23727606
    [Abstract] [Full Text] [Related]

  • 18. Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer.
    Sheng J, Fang W, Yu J, Chen N, Zhan J, Ma Y, Yang Y, Huang Y, Zhao H, Zhang L.
    Sci Rep; 2016 Jan 29; 6():20090. PubMed ID: 26822379
    [Abstract] [Full Text] [Related]

  • 19. Prognostic value of programed death ligand 1 in patients with solid tumors: A meta-analysis.
    Jin Y, Zhao J, Shi X, Yu X.
    J Cancer Res Ther; 2015 Aug 29; 11 Suppl 1():C38-43. PubMed ID: 26323922
    [Abstract] [Full Text] [Related]

  • 20. [PD-L1 expression: An emerging biomarker in non-small cell lung cancer].
    Adam J, Planchard D, Marabelle A, Soria JC, Scoazec JY, Lantuéjoul S.
    Ann Pathol; 2016 Jan 29; 36(1):94-102. PubMed ID: 26778219
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.